Theriva Biologics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TOVX research report →
Companytherivabio.com
Theriva Biologics Inc. , a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
- CEO
- Steven A. Shallcross
- IPO
- 2006
- Employees
- 20
- HQ
- Rockville, MD, US
Price Chart
Valuation
- Market Cap
- $10.71M
- P/E
- -0.57
- P/S
- 35.69
- P/B
- 0.80
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.00%
- Op Margin
- -7245.00%
- Net Margin
- -7153.00%
- ROE
- -178.29%
- ROIC
- -76.19%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-25,249,000 · 1.57%
- EPS
- $-2.08 · 89.07%
- Op Income
- $-15,020,000
- FCF YoY
- 1.38%
Performance & Tape
- 52W High
- $0.86
- 52W Low
- $0.16
- 50D MA
- $0.28
- 200D MA
- $0.29
- Beta
- 1.18
- Avg Volume
- 21.92M
Get TickerSpark's AI analysis on TOVX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 5, 26 | SHALLCROSS STEVEN A | other | 475,000 |
| Jan 5, 26 | MONAHAN JOHN J | other | 75,000 |
| Jan 5, 26 | Kraws Jeffrey J | other | 75,000 |
| Jan 5, 26 | Wolf Jeffrey Alan | other | 75,000 |
| Apr 29, 25 | Wolf Jeffrey Alan | other | 25,000 |
| Apr 29, 25 | SHALLCROSS STEVEN A | other | 190,000 |
| Apr 29, 25 | MONAHAN JOHN J | other | 25,000 |
| Apr 29, 25 | Kraws Jeffrey J | other | 25,000 |
| Dec 14, 23 | SHALLCROSS STEVEN A | other | 700,000 |
| Dec 14, 23 | Wolf Jeffrey Alan | other | 110,000 |
Our TOVX Coverage
We haven't published any research on TOVX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TOVX Report →